J Allergy Clin Immunol Pract. 2024 May 18:S2213-2198(24)00530-0. doi: 10.1016/j.jaip.2024.05.016. Online ahead of print.
ABSTRACT
BACKGROUND: Biologic effectiveness is often assessed as ‘response’, a term which eludes consistent definition. Identifying those most likely to respond in real-life has proven challenging.
OBJECTIVE: To explore definitions of biologic responders in adults with severe asthma and investigate patient characteristics associated with biologic response.
METHODS: This was a longitudinal cohort study using data from 21 countries, which shared data with the International Severe Asthma Registry. Changes in 4 asthma outcome domains were assessed in the 1-year period pre- and post-biologic-initiation in patients with predefined level of pre-biologic impairment. Responder cut-offs were: ≥50% reduction in exacerbation rate, ≥50% reduction in long-term oral corticosteroid [LTOCS] daily dose, ≥1 category improvement in asthma control, and ≥100mL improvement in FEV1. Responders were defined using single- and multiple-domains. The association between pre-biologic characteristics and post-biologic-initiation response were examined by multivariable analysis.
RESULTS: 2,210 patients were included. Responder rate ranged from 80.7% (n=566/701) for exacerbation-response to 10.6% (n=9/85) for 4-domain-response. Many responders still exhibited significant impairment post-biologic-initiation: 46.7% (n=206/441) of asthma control-responders with uncontrolled asthma pre-biologic still had incompletely-controlled disease post-biologic-initiation. Predictors of response were outcome-dependent. Lung function-responders were more likely to have higher pre-biologic FeNO (OR:1.20 for every 25ppb increase), and shorter asthma duration (OR:0.81, for every 10-year increase in duration). Higher BEC and presence of T2-related comorbidities were positively associated with higher odds of meeting LTOCS-, control- and lung function-responder criteria.
CONCLUSION: Our findings underscore the multi-modal nature of ‘response’, show that many responders experience residual symptoms post-biologic-initiation, and that predictors of response vary according to outcome assessed.
PMID:38768896 | DOI:10.1016/j.jaip.2024.05.016
